Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma

Wang,Jiang; Ren,Ye; Guo,Xin; Cheng,Hao; Ye,Yaping; Qi,Jun; Yang,Caihong; You,Hongbo

doi:10.3892/mmr.2015.3164

Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma

Authors:
- Jiang Wang
- Ye Ren
- Xin Guo
- Hao Cheng
- Yaping Ye
- Jun Qi
- Caihong Yang
- Hongbo You
View Affiliations

Affiliations: Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: January 8, 2015 https://doi.org/10.3892/mmr.2015.3164
Pages: 3585-3592

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma (RCC) has a high potential for bone metastasis; however, the molecular mechanisms underlying this metastasis have remained to be elucidated. The present study aimed to explore the expression levels of enhancer of zeste homolog 2 (EZH2), matrix metalloproteinase-2 (MMP2) and tissue inhibitor of metalloproteinase-2 (TIMP2) as determinants of RCC-associated bone metastasis. Their expression was evaluated in a newly generated RCC cell subline that has a high potential for bone metastasis, in tissue specimens from metastasized bone tissues from patients with RCC and in RCC tissues without metastasis. A total of 25 RCC tissue specimens without metastasis and 13 RCC tissue specimens with bone metastasis were acquired for immunohistochemical analysis of EZH2, MMP2 and TIMP2 protein expression. The expression levels of EZH2, MMP2 and TIMP2 mRNA and protein were analyzed in the ACHN and ACHN-BO5 cell lines using western blot and reverse transcription polymerase chain reaction (PCR) analyses. Methylation-specific PCR was also used to analyze TIMP2 promoter methylation. EZH2 and MMP2 proteins were found to be expressed at higher levels in tissues from patients where RCC had metastasized to the bone as compared with those in RCC patients without metastasis, whereas there was no significant difference in the expression of TIMP2 protein between the two tissues. Furthermore, the expression of EZH2 protein was correlated with MMP2 expression, but there was no significant correlation between the expression of EZH2 and TIMP2 proteins. The in vitro results using cell lines confirmed the ex vivo findings, indicating that the expression levels of EZH2 and MMP2 protein and mRNA were higher in ACHN-BO5 cells than those in ACHN cells. By contrast, TIMP2 protein and mRNA expression levels were lower in ACHN-BO5 cells than those in the parental ACHN cells. The TIMP2 promoter was highly methylated in ACHN-BO5 cells compared with that in ACHN cells. Upregulation of EZH2, MMP2 and TIMP2 expression was correlated with metastasis of RCC to bone tissues ex vivo and in vitro. Further studies are required in order to elucidate the mechanism underlying the altered expression of these genes.

View Figures

View References

1	Kosary C and McLaughlin J: Kidney and renal pelvis. Cancer Statistics Review: 1973–1990. Miller BA, Ries LAG, Hankey BE, et al: National Institutes Of Health; Bethesda: pp. x1–x22. 1993
2	Fleming S and Lewi H: Collecting duct carcinoma of the kidney. Histopathology. 10:1131–1141. 1986. View Article : Google Scholar : PubMed/NCBI
3	Thoenes W, Störkel S and Rumpelt H: Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract. 181:125–143. 1986. View Article : Google Scholar : PubMed/NCBI
4	Pisani P, Parkin D and Ferlay J: Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer. 55:891–903. 1993. View Article : Google Scholar : PubMed/NCBI
5	Ritchie A and Chisholm G: The natural history of renal carcinoma. Semin Oncol. 10:390–400. 1983.PubMed/NCBI
6	Wood SL and Brown JE: Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev. 38:284–291. 2012. View Article : Google Scholar
7	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
8	Erdoğan F, Demirel A and Polat O: Prognostic significance of morphologic parameters in renal cell carcinoma. Int J Clin Pract. 58:333–336. 2004. View Article : Google Scholar
9	Wang J, Chen A, Yang C, Zeng H, Qi J and Guo FJ: A bone-seeking clone exhibits different biological properties from the ACHN parental human renal cell carcinoma in vivo and in vitro. Oncol Rep. 27:1104–1110. 2012.
10	Gibson WT, Hood RL, Zhan SH, et al; FORGE Canada Consortium. Mutations in EZH2 cause Weaver syndrome. Am J Hum Genet. 90:110–118. 2012. View Article : Google Scholar :
11	Weaver DD, Graham CB, Thomas I and Smith DW: A new overgrowth syndrome with accelerated skeletal maturation, unusual facies, and camptodactyly. J Pediatr. 84:547–552. 1974. View Article : Google Scholar : PubMed/NCBI
12	Kleer CG, Cao Q, Varambally S, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
13	Kehinde EO, Maghrebi M and Anim JT: The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers. Can J Urol. 15:3967–3974. 2008.PubMed/NCBI
14	Simon JA and Lange CA: Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 647:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
15	Varambally S, Cao Q, Mani RS, et al: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 322:1695–1699. 2008. View Article : Google Scholar : PubMed/NCBI
16	Shen L, Cui J, Liang S, Pang Y and Liu P: Update of research on the role of EZH2 in cancer progression. Onco Targets Ther. 6:321–324. 2013. View Article : Google Scholar : PubMed/NCBI
17	Nagase H and Woessner JF Jr: Matrix metalloproteinases. J Biol Chem. 274:21491–21494. 1999. View Article : Google Scholar : PubMed/NCBI
18	Shi SR, Key ME and Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 39:741–748. 1991. View Article : Google Scholar : PubMed/NCBI
19	Nguyen DX and Massagué J: Genetic determinants of cancer metastasis. Nat Rev Genet. 8:341–352. 2007. View Article : Google Scholar : PubMed/NCBI
20	Wong GS and Rustgi AK: Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. Br J Cancer. 108:755–761. 2013. View Article : Google Scholar : PubMed/NCBI
21	Drabsch Y and ten Dijke P: TGF-β signaling in breast cancer cell invasion and bone metastasis. J Mammary Gland Biol Neoplasia. 16:97–108. 2011. View Article : Google Scholar : PubMed/NCBI
22	Zlotnik A, Burkhardt AM and Homey B: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 11:597–606. 2011. View Article : Google Scholar : PubMed/NCBI
23	Chen H, Rossier C and Antonarakis SE: Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2. Genomics. 38:30–37. 1996. View Article : Google Scholar : PubMed/NCBI
24	Cardoso C, Timsit S, Villard L, Khrestchatisky M, Fontès M and Colleaux L: Specific interaction between the XNP/ATR-X gene product and the SET domain of the human EZH2 protein. Hum Mol Genet. 7:679–684. 1998. View Article : Google Scholar : PubMed/NCBI
25	Heinen A, Tzekova N, Graffmann N, et al: Histone methyltransferase enhancer of zeste homolog 2 regulates Schwann cell differentiation. Glia. 60:1696–1708. 2012. View Article : Google Scholar : PubMed/NCBI
26	Xia H, Yu CH, Zhang Y, et al: EZH2 silencing with RNAi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo. Oncol Lett. 4:135–140. 2012.PubMed/NCBI
27	Cho HM, Jeon HS, Lee SY, et al: microRNA-101 inhibits lung cancer invasion through the regulation of enhancer of zeste homolog 2. Exp Ther Med. 2:963–967. 2011.
28	Kikuchi J, Takashina T, Kinoshita I, et al: Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 78:138–143. 2012. View Article : Google Scholar : PubMed/NCBI
29	Marchesi I, Fiorentino FP, Rizzolio F, Giordano A and Bagella L: The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation. Cell Cycle. 11:3828–3836. 2012. View Article : Google Scholar : PubMed/NCBI
30	Zhou J, Roh JW, Bandyopadhyay S, et al: Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol Oncol. 128:344–348. 2013. View Article : Google Scholar
31	Wan L, Li X, Shen H and Bai X: Quantitative analysis of EZH2 expression and its correlations with lung cancer patients’ clinical pathological characteristics. Clin Transl Oncol. 15:132–138. 2013. View Article : Google Scholar
32	Zhang R, Wang R, Chang H, et al: Downregulation of Ezh2 expression by RNA interference induces cell cycle arrest in the G0/G1 phase and apoptosis in U87 human glioma cells. Oncol Rep. 28:2278–2284. 2012.PubMed/NCBI
33	Wagener N, Macher-Goeppinger S, Pritsch M, et al: Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer. 10:5242010. View Article : Google Scholar : PubMed/NCBI
34	Wagener N, Holland D, Bulkescher J, et al: The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer. 123:1545–1550. 2008. View Article : Google Scholar : PubMed/NCBI
35	Hinz S, Weikert S, Magheli A, et al: Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma. J Urol. 182:2920–2925. 2009. View Article : Google Scholar : PubMed/NCBI
36	Sakurai T, Bilim VN, Ugolkov AV, et al: The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells. Biochem Biophys Res Commun. 422:607–614. 2012. View Article : Google Scholar : PubMed/NCBI
37	Li K, Chen MK, Situ J, et al: Role of co-expression of c-Myc, EZH2 and p27 in prognosis of prostate cancer patients after surgery. Chin Med J (Engl). 126:82–87. 2013.
38	Yang YA and Yu J: EZH2, an epigenetic driver of prostate cancer. Protein Cell. 4:331–341. 2013. View Article : Google Scholar : PubMed/NCBI
39	Takeshita F, Minakuchi Y, Nagahara S, et al: Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA. 102:12177–12182. 2005. View Article : Google Scholar : PubMed/NCBI
40	Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T and Garnero P: Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer. 95:506–514. 2006. View Article : Google Scholar : PubMed/NCBI
41	Andela VB, Gordon AH, Zotalis G, et al: NFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res. (415 Suppl): S75–S85. 2003. View Article : Google Scholar : PubMed/NCBI
42	Lhoták S, Elavathil LJ, Vukmirović-Popović S, Duivenvoorden WC, Tozer RG and Singh G: Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma. Clin Exp Metastasis. 18:463–470. 2000. View Article : Google Scholar
43	Yoneda T, Sasaki A, Dunstan C, et al: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest. 99:2509–2517. 1997. View Article : Google Scholar : PubMed/NCBI
44	Hsu CH, Peng KL, Kang ML, et al: TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2:568–579. 2012. View Article : Google Scholar : PubMed/NCBI
45	Shin YJ and Kim JH: The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. PloS One. 7:e303932012. View Article : Google Scholar : PubMed/NCBI
46	Fornari F, Milazzo M, Chieco P, et al: In hepatocellular carcinoma miR-519d is upregulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J Pathol. 227:275–285. 2012. View Article : Google Scholar : PubMed/NCBI
47	Matsusaka K, Kaneda A, Nagae G, et al: Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 71:7187–7197. 2011. View Article : Google Scholar : PubMed/NCBI
48	Hervouet E, Vallette FM and Cartron PF: Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation. Epigenetics. 4:487–499. 2009. View Article : Google Scholar : PubMed/NCBI
49	Martinez R, Schackert G and Esteller M: Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme. J Neurooncol. 82:133–139. 2007. View Article : Google Scholar
50	Chu LC, Eberhart CG, Grossman SA and Herman JG: Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer. 119:2487–2491. 2006. View Article : Google Scholar : PubMed/NCBI
51	Crea F, Fornaro L, Bocci G, et al: EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev. 31:753–761. 2012. View Article : Google Scholar : PubMed/NCBI